Monograph
L01XD03 - Methyl Aminolevulinate |
Not porphyrinogenic |
NP |
Rationale
Insignificant systemic exposure. No phototoxic effects outside the skin application site.
Chemical description
Methyl aminolevulinate is a linear metylated five carbon molecule. After tissue demetylation it constitutes the initial precursor in porphyrin biosynthesis.
Therapeutic characteristics
Methyl aminolevulinate hydrochloride is a derivative of 5-aminolevulinic acid that is applied topically for the treatment of non-hyperkeratotic, non-pigmented actinic keratoses of the face or scalp, and in the treatment of superficial and/or nodular basal cell carcinoma.
Hepatic exposure
Not significant.
Metabolism and pharmacokinetics
Metabolized in situ to phototoxic porphyrins. In-vitro studies of dermal absorption found that the mean cumulative absorption of methyl aminolevulinate through healthy human skin after 24 hours was 0.26% of a dose.
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | Sweetman SC, editor. Martindale: The complete drug reference. Methyl aminolevulinate Hydrochlorid. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Metvix.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Luxembourg
Iceland
Finland© NAPOS 2024